G6PD and COVID-19: Genetic testing confirmed the A– variant in the case presented by Kuipers et al. Whereas CQ is not known to induce severe haemolytic effects when used as an antimalarial in G6PD deficient individuals, in contrast to primaquine [22] or chloroproguanil [23], the risk of its therapeutic use in G6PD deficient, COVID-19 patients has been observed in case reports, but requires further study.